尼古丁(Nicotine) - 药物靶点：Muscle-type nAChRs_在研适应症：烟草依赖，尼古丁依赖，肺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(S)-(−)-nicotine、(S)-3-(1-methylpyrrolidin-2-yl)pyridine、(S)-3-(N-methylpyrrolidin-2-yl)pyridine

+ [31]

靶点

Muscle-type nAChRs

作用方式

激动剂

作用机制

Muscle-type nAChRs激动剂(肌肉型烟碱乙酰胆碱受体复合体激动剂)

治疗领域

其他疾病肿瘤呼吸系统疾病

在研适应症

烟草依赖尼古丁依赖肺癌+ [1]

非在研适应症

肢端雀斑恶性黑色素瘤药物性运动障碍帕金森病

原研机构

Neuraltus Pharmaceuticals, Inc.

在研机构

Haleon US Capital LLC

Johnson & Johnson Pacific Pty Ltd.McNeil Sweden AB

+ [6]

非在研机构

Haleon Plc

Janssen Pharmaceuticals, Inc.

Neuraltus Pharmaceuticals, Inc.

+ [2]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1984-01-13),

尼古丁依赖

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H14N2

InChIKeySNICXCGAKADSCV-JTQLQIEISA-N

CAS号54-11-5

关联

704

项与尼古丁相关的临床试验

NCT06811038

/ Not yet recruiting临床3期IIT

Providing Nicotine Replacement Therapy to Enhance the Efficacy of a Smoking Cessation Smartphone App for Hispanic Adults

This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.

开始日期2025-06-01

申办/合作机构

Fred Hutchinson Cancer Research Center

[+1]

NCT06334016

/ Not yet recruiting早期临床1期IIT

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study

This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.

开始日期2025-05-27

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT05999383

/ Not yet recruiting临床2期IIT

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.

开始日期2025-05-01

申办/合作机构

The University of California, San Francisco

[+3]

100 项与尼古丁相关的临床结果

登录后查看更多信息

100 项与尼古丁相关的转化医学

登录后查看更多信息

100 项与尼古丁相关的专利（医药）

登录后查看更多信息

50,501

项与尼古丁相关的文献（医药）

2025-09-01·TALANTA

A diverse paper sensor for the rapid determination of nicotine and cotinine traces in air, vaping liquid, and human saliva

Article

作者: Nihal, Serena ; Nihal, Aneel ; Sarfo, Daniel ; Izake, Emad L ; Sonar, Prashant ; Tesfamichael, Tuquabo ; Ayoko, Godwin

The smoking of nicotine and passive exposure to environmental tobacco smoke can lead to many chronic medical conditions such as respiratory, cardiovascular, and cancer diseases. Nicotine smoking can also cause complications for patients undergoing medical procedures. The prevalence of vaping among young people has added a significant challenge to the health care systems as many commercial vaping oils contain undeclared nicotine content, thus leading to nicotine addiction. Governments around the world criminalised the undeclared presence of nicotine in vaping oils. Therefore, there a is strong demand for new materials and sensors that can rapidly detect nicotine/tobacco smoke in vaping products and the environment. Similarly, there is an ongoing need for rapid methods to determine the concentration of the nicotine metabolite, cotinine, in patients prior to medical procedures. To address these needs, we have synthesised and utilised a cost-effective paper sensor for the rapid screening of nicotine and cotinine in vaping the oil, the gas phase, and the human saliva by surface-enhanced Raman spectroscopy (SERS). The new sensor can detect ultra traces of nicotine and cotinine down to 1 pg/mL and 1 ng/mL respectively, within 20 min. The new sensor can be recycled for repeated screening of nicotine and its metabolite, thus maximizing its economic viability. The was successfully utilised for the detection of nicotine in tobacco smoke and in spiked human saliva by a handheld Raman spectrometer, thus indicating its potential for real-life applications.

2025-08-01·ADDICTIVE BEHAVIORS

Switching between vaping devices, nicotine concentration, and flavors among people who use e-cigarettes daily: Results from a 12-Month longitudinal study

Article

作者: Block, Ashleigh C ; Martin, Connor D ; Kaiser, Lisa M ; Miller, Connor R ; Goniewicz, Maciej L

BACKGROUND:

E-cigarettes vary widely in product characteristics (e.g., device type, nicotine concentration, and flavor). Little is known about how people who use e-cigarettes switch between products with different characteristics. We tracked the stability/variability in characteristics of products used by individuals who vaped e-cigarettes daily over one year.

METHODS:

Of 126 enrolled participants who vaped e-cigarettes daily and did not use other nicotine products, 80 completed 12 monthly study visits. Participants reported device type, nicotine concentration, and flavors used in the past 30 days at each visit. Participants were also asked to bring e-cigarette devices and e-liquids to each visit. Study staff took pictures of products carried by participants and categorized product characteristics.

RESULTS:

Over one year, 35.0 % of participants did not change device type, nicotine concentration, or flavor type. However, 35 % of participants changed device type, 31.3 % changed nicotine concentration, and 46.3 % changed flavor at least once. The most common change in device type was switching from open to closed system devices (67.9 %). The rate of switching from low to high nicotine (≤24 vs. > 24 mg/mL) was more common than the reverse (56.6 % vs. 43.4 %). The most common change in flavor was switching between Fruit/Sweet and Hybrid (Fruit/Sweet with a cooling additive, 75.7 % of flavor switching events).

CONCLUSIONS:

Most study participants switched one product characteristic at least once during a 12-month study period. Users most frequently switched flavors and least frequently switched nicotine concentrations. Future studies should consider the variability of product use patterns among people who use e-cigarettes.

2025-08-01·ADDICTIVE BEHAVIORS

Nicotine and cannabis vaping-related workplace absenteeism among U.S. Adults, 2022

Article

作者: Yang, Kevin H ; Palamar, Joseph J ; Urban, Cooper

INTRODUCTION:

Vaping of nicotine and cannabis has increased substantially among US adults, but its impact on workplace productivity remains poorly understood. This study examines the associations between nicotine and cannabis vaping patterns and workplace absenteeism.

METHODS:

Cross-sectional data from a US nationally representative sample of noninstitutionalized part-time and full-time employed adults aged ≥ 18 from the 2022 National Survey on Drug Use and Health (N = 30,591) were analyzed. The associations between nicotine vaping (recency and frequency), cannabis vaping (recency), and workplace absenteeism (measured by self-reported number of missed days due to illness/injury and skipped work in the past month) were evaluated using negative binomial regression adjusting for sociodemographic characteristics and other past-month drug use.

RESULTS:

An estimated 10.4 % of full-time workers vaped nicotine in the past month and 6.4 % vaped cannabis. Compared to never-vapers of nicotine, those with any history of vaping had higher estimated incidence of absences with past-month vaping associated with increased incidence of missed work due to illness/injury (aIRR = 1.34, 95 % CI: 1.14-1.59) and skipping work (aIRR = 1.65, 95 % CI: 1.24-2.21). Past-month cannabis vaping was associated with increased estimated incidence of missed work due to illness/injury (aIRR = 1.35, 95 % CI: 1.06-1.72) and skipping work (aIRR = 1.70, 95 % CI: 1.32-2.18), although these rates did not differ significantly from those associated with non-vaped cannabis use. Associations were generally stronger among full-time workers compared to part-time workers.

CONCLUSION:

Both nicotine and cannabis vaping are associated with increased workplace absenteeism. Results support the development and implementation of workplace policies to address vaping-related productivity losses.

314

项与尼古丁相关的新闻（医药）

2025-05-08

·药明康德

70%患者症状缓解，突破性疗法今年递交上市申请；GSK小分子达3期临床主要终点……

70%患者症状缓解，抗体疗法获FDA突破性疗法认定Viridian Therapeutics公司日前宣布，其在研候选药物veligrotug已获得美国FDA授予的突破性疗法认定。Veligrotug是一款靶向胰岛素样生长因子-1受体（IGF-1R）的静脉输注抗体，正在3期临床试验中用于治疗甲状腺相关眼病（TED）。该公司预计在今年下半年向美国FDA递交生物制品许可申请（BLA）。在关键性3期临床试验THRIVE和THRIVE-2中，veligrotug达到了所有主要和次要研究终点。Veligrotug在两项临床研究中均展现出起效迅速，并在复视缓解和消除方面提供具有统计学显著性和临床意义的改善。此前公布THRIVE试验结果显示，在第15周时，接受veligrotug治疗患者的眼球突出缓解率为70%，安慰剂调整后的眼球突出缓解率为64%（p<0.0001）。值得一提的是，53%的患者3周内眼球突出症状就获得显著改善，此时他们只接受过一次治疗。56%患者瘙痒症状大幅缓解，GSK公司小分子药物达到3期临床主要终点GSK公司今日宣布，3期临床试验GLISTEN取得积极结果。该试验评估了在患有胆汁淤积性瘙痒症和原发性胆汁性胆管炎（PBC）成年患者中，靶向回肠胆汁酸转运蛋白（IBAT）的在研药物linerixibat的疗效。GLISTEN试验达到主要终点，结果显示，接受linerixibat治疗的患者（n=119）在24周内瘙痒显著改善，优于安慰剂组（n=119）。通过最严重瘙痒程度的数值评分量表（WI-NRS）进行评估，两组之间的最小二乘均值差为-0.72（95% CI：-1.15，-0.28，p=0.001）。该结果显示，linerixibat有望缓解PBC患者的一项主要症状——顽固性瘙痒。该研究还达成多个关键次要终点，包括第2周瘙痒评分改善及24周内瘙痒相关睡眠干扰评分的改善，具体表现如下：瘙痒改善起效迅速，第2周即优于安慰剂组，差异具有统计学意义（最小二乘均值差为-0.71，95% CI：-1.07，-0.34，p<0.001），且疗效在整个试验周期内持续维持。在24周的治疗周期中，与安慰剂相比，linerixibat显著改善了瘙痒引起的睡眠干扰，该症状对患者生活质量影响显著。到第24周，linerixibat组中有56%的患者瘙痒评分改善具有临床意义（WI-NRS降低≥3分），而安慰剂组为43%，治疗组之间的差异为13%（95% CI：0，27）。开发RNA靶向疗法，新锐完成6500万美元A轮融资HAYA Therapeutics今日宣布完成6500万美元的A轮融资。此次融资将加速公司核心在研长链非编码RNA（lncRNA）靶向候选药物HTX-001在心力衰竭领域的临床开发，并推动其RNA引导基因调控平台的持续拓展。HAYA Therapeutics是一家精准医疗公司，致力于开发可编程疗法，靶向调节性非编码RNA，以重新编程包括心血管疾病、代谢疾病和癌症在内多种疾病的病理细胞状态。该公司正在利用其创新平台深入解析疾病细胞状态及其所涉及的lncRNA调控机制。HAYA的主打项目是HTX-001，正在开发用于治疗心力衰竭。HAYA还在开发一系列靶向lncRNA的精准疗法，用于针对其他组织疾病的细胞特异性治疗。去年9月，HAYA与礼来（Eli Lilly and Company）达成一项总额高达10亿美元的多年协议。两家公司将应用HAYA的RNA引导基因调控平台来支持肥胖和相关代谢疾病的临床前药物研发工作。参考资料：[1] HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases. Retrieved May 8, 2025, from https://www.hayatx.com/news-and-publications/haya-therapeutics-raises-65-million-in-series-a-funding-to-deliver-precision-rna-guided-medicines-for-chronic-and-age-related-diseases[2] Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED). Retrieved May 8, 2025, from https://www.businesswire.com/news/home/20250507164030/en/Viridian-Therapeutics-Receives-FDA-Breakthrough-Therapy-Designation-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease-TED[3] GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC). Retrieved May 8, 2025, from https://www.gsk.com/en-gb/media/press-releases/glisten-phase-iii-trial-results-show-linerixibat-significantly-improves-cholestatic-pruritus/免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

突破性疗法临床结果临床3期

2025-05-07

·金诃藏药

世界卵巢癌日：守护女性卵巢健康，高原藏医药的妇科智慧

每年的5月8日是世界卵巢癌日，旨在提高公众对卵巢癌的认识，增强女性对卵巢健康的关注。卵巢，作为女性重要的生殖器官，不仅承担着排卵的重任，还分泌着雌激素、孕激素等多种激素，对维持女性的生理特征、生殖功能以及整体健康起着关键作用。然而，卵巢疾病却如同隐藏在暗处的 “杀手”，时刻威胁着女性的健康。卵巢疾病的危害与现状卵巢疾病种类繁多，包括卵巢囊肿、卵巢早衰、多囊卵巢综合征，甚至是令人谈之色变的卵巢癌。卵巢囊肿可能会导致腹痛、月经紊乱，若囊肿破裂或扭转，还会引发急腹症，危及生命。卵巢早衰使女性提前进入 “更年期”，出现潮热、盗汗、失眠、情绪波动等症状，加速衰老进程，还可能导致不孕。多囊卵巢综合征则常伴有月经不调、多毛、肥胖等问题，影响女性的外貌和生育能力。而卵巢癌，因其早期症状隐匿，往往发现时已处于晚期，死亡率在妇科恶性肿瘤中居首位。据统计，全球每年约有 23 万女性被诊断为卵巢癌，15 万女性因卵巢癌离世，这些冰冷的数据背后，是一个个破碎的家庭和消逝的生命，卵巢健康问题亟待引起重视。卵巢疾病的预防方法定期体检女性应从青春期开始，定期进行妇科检查，包括妇科超声、肿瘤标志物检测等。一般建议每年进行一次全面的妇科体检，对于有家族遗传史等高危因素的女性，检查频率应适当增加，可每半年检查一次。通过定期体检，能够早期发现卵巢的微小病变，及时采取干预措施，提高治疗效果。保持健康生活方式均衡饮食至关重要，多摄入富含维生素 C、维生素 E、叶酸等抗氧化物质的食物，如柑橘类水果、坚果、绿叶蔬菜等，这些营养物质有助于抵抗自由基对卵巢细胞的损伤。同时，要减少高脂肪、高糖、高盐食物的摄入，避免过度肥胖，因为肥胖会影响内分泌系统，增加患卵巢疾病的风险。此外，适量运动也不可或缺，每周坚持 150 分钟以上的中等强度有氧运动，如快走、慢跑、游泳等，运动不仅能增强体质，还能调节内分泌，改善卵巢功能。避免不良习惯吸烟、酗酒对卵巢健康危害极大。香烟中的尼古丁等有害物质会干扰卵巢的正常功能，导致卵巢早衰。酒精则可能影响激素的代谢，增加患卵巢疾病的几率。因此，女性应尽量避免吸烟、酗酒，保持良好的生活习惯。饮食调理方案日常饮食：日常饮食应注重营养均衡。早餐可选择全麦面包搭配低脂牛奶、水煮蛋，再加上一份新鲜水果，为身体提供丰富的碳水化合物、蛋白质、维生素等营养物质。午餐和晚餐以瘦肉、鱼类、豆类等优质蛋白质为主，搭配大量的蔬菜，如西兰花、胡萝卜、菠菜等，蔬菜富含膳食纤维和多种维生素，有助于促进肠道蠕动，排出体内毒素。此外，每周可食用 2 - 3 次坚果，如杏仁、核桃等，坚果中的不饱和脂肪酸对卵巢健康有益。特殊时期饮食在经期，女性身体较为虚弱，可适当食用一些温热、易消化的食物，如红枣桂圆粥、红糖姜水等，有助于暖宫散寒，缓解经期不适。而在排卵期，可多吃一些富含雌激素的食物，如豆类及其制品，大豆中含有的大豆异黄酮具有类似雌激素的作用，能调节女性体内的激素水平，维持卵巢正常功能。藏医对妇科疾病的病因认识及防治思路藏医药有着悠久的历史和独特的理论体系，对妇科疾病的认识和治疗有着独到之处。在藏医理论中，人体由 “隆”“赤巴”“培根” 三大因素维持平衡，当这三大因素失调时，就会引发各种疾病，妇科疾病也不例外。病因认识藏医认为，女性长期处于焦虑、抑郁等不良情绪中，会导致 “隆” 气紊乱，影响气血运行，从而引发妇科疾病。此外，饮食不节，如过食辛辣、油腻、生冷食物，以及起居无常，过度劳累或受寒等，也会导致体内三因失衡，使妇科疾病乘虚而入。例如，长期食用生冷食物，会损伤 “培根”，导致寒凝气滞，引发痛经、月经不调等疾病。防治思路藏医药治疗妇科疾病注重整体调理，通过调节人体的三因平衡，达到治疗疾病的目的。在治疗过程中，藏医会根据患者的具体症状、体征以及舌象、脉象等，进行辨证论治，制定个性化的治疗方案。治疗方法包括药物治疗、饮食调理、起居指导以及外治疗法等。例如，对于月经不调的患者，藏医可能会采用活血化瘀、调理气血的药物进行治疗，同时嘱咐患者注意饮食清淡，避免劳累，保持心情舒畅。二十五味鬼臼丸在藏医药治疗妇科疾病的药物中，二十五味鬼臼丸是经典方剂。它由鬼臼、藏茜草、石榴子、藏紫草、肉桂等二十五味药材组成。鬼臼具有祛风除湿、化痰散结、解毒止痛的功效，能有效调节女性内分泌，缓解妇科炎症。藏茜草活血化瘀、凉血止血，可改善女性月经不调、痛经等症状。石榴子温肾助阳，对女性肾阳不足引起的各种症状有很好的疗效。藏紫草凉血，活血，解毒透疹，有助于清除体内热毒。肉桂补火助阳、散寒止痛，能温通经脉，改善寒凝气滞的状况。诸药合用，二十五味鬼臼丸具有祛风镇痛、调经血的功效，可用于治疗妇女血症、风症，子宫虫病，下肢关节疼痛，小腹、肝、胆、上体疼痛，心烦血虚，月经不调等多种妇科疾病。在卵巢疾病的治疗中，对于因气血不畅、寒凝气滞等原因导致的卵巢囊肿、月经紊乱等症状，二十五味鬼臼丸也能发挥一定的治疗作用，帮助患者缓解症状，促进身体恢复。在世界卵巢癌日这个特殊的日子里，让我们共同关注女性卵巢健康。通过了解卵巢疾病的预防方法、饮食调理方案以及康复建议，结合藏医药的智慧，更好地守护女性的卵巢健康，让每一位女性都能绽放出属于自己的健康光彩。编辑：程晓辉；审核：陈文文；总编：牛豫娟

2025-05-03

·循因缉药

Exact Sciences 2025Q1筛查业务再次下滑

球视野，深度视角各位亲爱的股东，大家早上好中午好晚上好！星球首发，加入方法如下。小编在这里！星球在这里！肠癌早筛龙头Exact Sciences发布2025Q1财报了，毫无意外，又是两位数的同比增长。但是，他真的是那么好吗？看完财报，我们内心实际上是在打鼓的。接下来，我们详细来看下这份财报。我们也会参考部分财报会的内容，具体原文可能没办法展示，会标注出来。#01明增实降2025Q1财报发表于2025年5月1日，Exact Sciences表示公司的本季度营收达到7.07亿美元，同比增长11%。核心的筛查业务营收5.4亿美元，同比增长14%。万年老大难精准肿瘤业务继续吊车尾，营收1.67亿美元，同比增长4%。然而，这个数据是有水分的。我们看这张图，Exact的筛查业务虽然同比大幅度增长，那是因为2024Q1的基数低。且，5.4亿美元的这个数字环比还是下滑的。这是近4年来第二次出现这个情况了，第一次就是2024Q1。只不过，随后2024年的走势一路高歌猛进罢了。还有另外一个有意思的点，让人觉得2025Q1有点历史重演的既视感。2024Q1和2025Q1这两个季度都相对于前面几个季度亏损突然扩大，注意这里2024Q4的亏损扣除了收购Thrive的减值损失。历史不会简单的重复，对吧？明升暗降，Exact你这学坏了啊。反正，感觉就是有点露怯了。#02露怯曾经，Exact可是大大方方的在这张ppt里告诉大家商务和研发团队人数的。结果这次，就放了个总人数。大家看这张图，会觉得Exact这个季度真不错。然而，如果放上2024Q4的结果就...Exact是真的想证明自己啊...#03也没那么糟Exact还表示，自家的触达率同比提升了30%。这个触达率，大家肯定很好奇是什么意思。幸运的是，有分析师跟我们一样好奇。这这个触达率是指拜访次数（dot calls），嗯，很科学。另外，订购方的数量已经超过1.9万家，相较于同期提升了10%。这确实可以提高Exact的触达率，值得肯定。另外，2025Q1的Cologuard订单中有25%来自再筛查（rescreen）。而2025年，大约有超过200万患者符合在筛查条件，相较于去年增长30%+。因此，2025年的Exact也没那么糟糕。唯一的问题是，这个符合再筛查的客户会不会去找Guardant...对于这一点，Exact也是心知肚明的。因此，自家的血液版肠癌早筛产品将在2025年夏季中期公布临床研究结果。呃，尴尬的一点是，Exact可能是特朗普新政的受害者。在回答血液版肠癌筛查进入指南的可能性时，公司认为这将是一个漫长的过程，因为美国预防服务工作组（USPSTF）的预算最近被削减，导致其会议时间不确定。没想到，世界线在这一刻收束了...#04未来Exact对于2025年的财务指引也进行了修订。其中，营收从30.25-30.85亿美元提高到30.7-31.2亿美元。同时，公司的调整后EBITDA从4.1-4.4亿美元提高到4.25-4.55亿美元。尽管我们对Exact有不少质疑，但是这个业绩还是给市场吃下了定心丸。因此，截止到撰稿时Exact股价上张11.92%。只不过，我们建议再看看Q2的表现也不迟吧。在目前这个宏观环境下，还是存在诸多变数。尤其是特朗普政府对FDA大幅度削减预算，虽然他们宣称不会影响新药/器械审批。谁知道呢。END小编在这里！星球在这里！各位股东看了么？赞了么？转发了么？别忘了点赞。谢谢！所有内容均不作为投资建议，信息均来自公开资料，星球更新更快。近期文章：诺唯赞海外营收悄悄破亿Guardant Health 多癌早筛性能首秀GeneDx：亏损、暴跌，但上调预期华大智造最新财报：咬定青山，一争长短NMPA WARNING：中国暂停印度VITAL LAB 地高辛原料药进口金域医学2024:哥们你是怎么做到的？相关资料：注1：https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/Exact-Sciences-Announces-First-Quarter-2025-Results/default.aspx注2：https://s22.q4cdn.com/877809405/files/doc_financials/2025/q1/1Q25-EXAS-presentation-vAC.pdf

财报并购

100 项与尼古丁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03365	尼古丁	N07BA01	DB00184

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
烟草依赖	澳大利亚	Johnson & Johnson Pacific Pty Ltd.	2001-11-27
尼古丁依赖	美国	Haleon US Capital LLC	1984-01-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肢端雀斑恶性黑色素瘤	临床3期	美国	McNeil AB	2011-03-01
尼古丁成瘾	临床3期	捷克	McNeil AB	1999-02-01
药物性运动障碍	临床2期	美国	Neuraltus Pharmaceuticals, Inc.	2009-10-01
帕金森病	临床2期	美国	Neuraltus Pharmaceuticals, Inc.	2009-10-01
肺癌	临床1期	美国	Pfizer Inc.	2017-06-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02265874 (CTgov)	临床1/2期	肺结节病	50	Habitrol (Treatment)	遞鑰憲憲選夢襯網鬱醖(鹽窪鹹艱鏇醖餘淵製鑰) = 積憲廠窪壓積鑰夢襯築壓壓鏇醖壓艱鏇網構憲 (獵網願衊蓋鑰膚廠鏇餘, 0.22) 更多	-	2025-04-24
				Placebo to Habitrol (Control)	遞鑰憲憲選夢襯網鬱醖(鹽窪鹹艱鏇醖餘淵製鑰) = 窪積網憲獵餘壓製夢鹹壓壓鏇醖壓艱鏇網構憲 (獵網願衊蓋鑰膚廠鏇餘, 0.04) 更多
NCT04994444 (CTgov)	临床2/3期	尼古丁成瘾	49	Nicoderm CQ (Preloading)	範觸廠艱蓋鬱願積願鬱(構醖觸範廠餘觸願窪獵) = 齋繭蓋糧鹽窪鑰膚蓋網淵獵壓範繭窪蓋廠獵鏇 (醖餘餘鹹廠廠醖蓋廠鏇, 13.2) 更多	-	2025-04-06
				Nicoderm CQ (Standard Treatment)	範觸廠艱蓋鬱願積願鬱(構醖觸範廠餘觸願窪獵) = 膚範製夢繭獵築鹹鑰鏇淵獵壓範繭窪蓋廠獵鏇 (醖餘餘鹹廠廠醖蓋廠鏇, 21.8) 更多
ISC2025	N/A	脑出血 nicotine exposure	-	Nicotine-exposed group	顧鏇淵築觸鹹製淵願襯(鏇夢餘餘壓壓糧構憲鑰) = 壓夢鹽夢襯襯壓鏇顧壓鏇選淵觸簾醖鑰蓋遞襯 (鏇襯鬱齋製膚淵鹹遞壓 )	积极	2025-01-30
				Nicotine (Saline (control) group)	顧鏇淵築觸鹹製淵願襯(鏇夢餘餘壓壓糧構憲鑰) = 鑰衊遞淵獵艱築繭夢繭鏇選淵觸簾醖鑰蓋遞襯 (鏇襯鬱齋製膚淵鹹遞壓 )
NCT04433767 (Pubmed)	临床2期	抑郁症 nicotine metabolite concentrations	29	Transdermal nicotine patches	製憲醖夢鑰襯鏇鹽願壓(壓膚夢選餘鹹廠製糧選) = improvement in self-reported affective symptoms (apathy, insomnia, rumination, and generalized anxiety symptoms), negativity bias, and disability 鏇鏇鑰簾鏇網淵憲製醖 (繭壓醖鬱夢願齋鬱鹹鏇 ) 更多	积极	2024-10-01
NCT05253573 (SurvLaos, CTgov)	临床2期	尼古丁成瘾 \| 肿瘤	80	Self-help materials (to support smoking cessation)+Nicotine patch (Automated Treatment)	艱構壓鑰醖簾鏇糧襯廠 = 簾顧鑰獵淵衊願鹹鏇鏇獵窪鑰鹽製顧襯獵願網 (獵鏇遞繭鬱壓鏇襯餘積, 膚憲衊築醖顧窪獵遞廠 ~ 鬱淵鏇壓範窪網衊糧鑰) 更多	-	2024-08-28
				Self-help materials (to support smoking cessation)+Nicotine patch (Standard Care)	艱構壓鑰醖簾鏇糧襯廠 = 醖艱鏇獵淵觸製網簾襯獵窪鑰鹽製顧襯獵願網 (獵鏇遞繭鬱壓鏇襯餘積, 膚蓋願蓋糧鹽遞積壓鏇 ~ 構繭觸築壓廠齋簾選廠) 更多
NCT03272685 (CTgov)	临床3期	尼古丁依赖	799	Very Low Nicotine Content Cigarettes (Very Low Nicotine Content Cigarettes)	糧網艱鏇壓獵遞獵遞廠(選窪襯襯壓築簾願遞淵) = 窪夢憲鏇簾壓遞衊衊鏇廠壓選鑰夢獵窪願選獵 (窪遞簾繭淵廠鑰衊鏇鏇, 7.88) 更多	-	2024-08-20
				Normal Nicotine Content Cigarettes (Normal Nicotine Content Cigarettes)	糧網艱鏇壓獵遞獵遞廠(選窪襯襯壓築簾願遞淵) = 獵遞積製廠鑰積繭獵膚廠壓選鑰夢獵窪願選獵 (窪遞簾繭淵廠鑰衊鏇鏇, 9.07) 更多
NCT03612960 (CTgov)	N/A	肢端雀斑恶性黑色素瘤	34	Very low nicotine content cigarettes (Very Low Nicotine Content Cigarettes)	鹹鏇糧襯廠簾鏇糧鬱餘(簾網顧夢憲觸窪鬱鹹憲) = 衊積餘鹹願憲範鑰製糧壓糧鏇壓廠構齋範襯繭 (齋鏇夢觸願蓋願築積顧, 0.18) 更多	-	2024-08-20
				Normal nicotine content cigarettes (Normal Nicotine Content Cigarettes)	鹹鏇糧襯廠簾鏇糧鬱餘(簾網顧夢憲觸窪鬱鹹憲) = 艱構鹹窪鹽簾淵鑰糧鹹壓糧鏇壓廠構齋範襯繭 (齋鏇夢觸願蓋願築積顧, 0.18) 更多
NCT03634839 (CTgov)	临床1期	烟草依赖	42	Flavoring Agents+Nicotine (Sweet Non-menthol, Nicotine 36mg/ml)	壓衊製蓋鹹憲膚壓夢廠(網餘憲淵艱觸壓積壓顧) = 鹽餘繭餘夢顧願獵遞鏇鬱壓觸憲醖鏇衊夢鬱獵 (積衊積選觸襯鹽網廠繭, 3.158) 更多	-	2024-08-09
				Flavoring Agents+Nicotine (Sweet Menthol, Nicotine 36mg/ml)	壓衊製蓋鹹憲膚壓夢廠(網餘憲淵艱觸壓積壓顧) = 鬱夢積範齋遞構網構廠鬱壓觸憲醖鏇衊夢鬱獵 (積衊積選觸襯鹽網廠繭, 3.158) 更多
NCT04974580 ((RISE), CTgov)	临床4期	尼古丁依赖	508	Phone Counseling (CoachingOnlyArm)	築獵鹹構顧鹹選鏇衊鹹 = 壓廠網壓願窪餘築艱夢糧壓顧餘簾願壓範範構 (夢憲觸積淵鏇鏇觸顧鑰, 觸選選繭蓋簾繭構鹹壓 ~ 選願鑰憲襯網觸餘選獵) 更多	-	2024-07-29
				Phone Counseling (DigitalArm)	築獵鹹構顧鹹選鏇衊鹹 = 艱鏇範衊鏇範蓋願糧衊糧壓顧餘簾願壓範範構 (夢憲觸積淵鏇鏇觸顧鑰, 鬱顧構繭繭夢鹽鹹窪積 ~ 糧觸廠壓範範鬱齋積選) 更多
NCT03611881 (ScreenASSIST, CTgov)	临床4期	肺癌 \| 吸烟	642	Nicotine Patch+Community Resource (Short, Short, Present)	齋廠觸餘衊衊夢壓膚鏇 = 襯壓遞襯廠鑰膚衊憲築顧齋獵範夢顧膚願憲艱 (範糧範構遞鹽積艱糧網, 繭衊觸艱範鏇鑰鏇蓋構 ~ 淵製衊範齋餘膚夢醖夢) 更多	-	2024-07-23
				Nicotine Patch+Community Resource (Short, Long, Present)	齋廠觸餘衊衊夢壓膚鏇 = 糧壓遞糧艱鏇選艱艱餘顧齋獵範夢顧膚願憲艱 (範糧範構遞鹽積艱糧網, 築糧衊鑰淵顧選醖簾壓 ~ 齋獵顧艱壓鏇淵齋鬱選) 更多